Sensidose is a pharmaceutical company that has developed an innovative system for the individualised dosing of tablets in Parkinson’s disease.
MyFID is a handheld programmable dosing device for tablets.
In the collaboration between Sensidose and NEP, NEP has worked with issues surrounding end-of-life care, as well as redesigning electronics and updating software and operating systems.
In relation to the product, NEP has developed a test system that enables the reliable testing of electronics in volume production.
